Fosamax Cost in New York 2026: What You'll Actually Pay for Alendronate

What Does Fosamax Actually Cost in New York Right Now?

Generic alendronate 70 mg tablets run about $15 per month at New York retail pharmacies in 2026 when purchased without insurance. Brand-name Fosamax carries a list price closer to $80 per month, though almost no cash-pay patient needs to pay that figure given the widespread availability of generics and discount programs. Choosing the generic from the moment you fill the prescription is the single fastest way to cut your out-of-pocket cost by more than 80 percent.

Alendronate belongs to the bisphosphonate drug class and received FDA approval in 1995 for postmenopausal osteoporosis [1]. The standard regimen is one 70 mg tablet taken orally on the same day each week, swallowed with a full glass of plain water at least 30 minutes before any food, beverage, or other medication. That once-weekly schedule means a standard 30-day supply actually contains only four or five tablets, which partly explains the low manufacturing cost and therefore the low generic price.

Prices vary by pharmacy chain. GoodRx and similar aggregators consistently show the 4-tablet (28-day) supply of generic alendronate 70 mg priced between $10 and $20 at major NY chains including CVS, Walgreens, Rite Aid, and Costco Pharmacy as of early 2026. Independent pharmacies in the five boroughs may price the same supply slightly higher or lower depending on their wholesaler contracts. Calling ahead or running a GoodRx coupon search for your specific ZIP code takes two minutes and can save several dollars per fill.

The fracture-prevention evidence that justifies this prescription is substantial. In the Fracture Intervention Trial (FIT, JAMA 1998, N=2,027), alendronate reduced the risk of new vertebral fractures by 47% compared with placebo over three years (relative risk 0.53 to 95% CI 0.41 to 0.68, P<0.001) [2]. Hip-fracture risk fell by a similar margin in the hip-fracture subgroup. That level of efficacy, combined with a sub-$20 monthly cash price, makes alendronate one of the most cost-effective fracture-prevention tools in outpatient medicine.

Quick cost-tier reference for NY patients (2026 estimates):

| Payment Method | Estimated Monthly Cost | |---|---| | Generic alendronate, no insurance | ~$15 | | Brand Fosamax, no insurance | ~$80 | | NY Medicaid (post-PA approval) | $0 copay or nominal copay | | Commercial insurance, Tier 1 | $0, $10 copay | | Commercial insurance, Tier 2 | $10, $40 copay | | 503A compounded alendronate | $0 (some programs) |

Does New York Medicaid Cover Fosamax or Generic Alendronate?

New York Medicaid covers alendronate, but prior authorization is required before the claim will adjudicate. The PA criteria under the New York State Medicaid fee-for-service formulary focus on confirmed diagnosis of osteoporosis or a documented fragility fracture, typically supported by a DXA scan showing a T-score of negative 2.5 or below, or a T-score between negative 1.0 and negative 2.5 with additional fracture risk factors per FRAX scoring.

Prescribers submit PA requests through the eMedNY system or through the managed care plan's portal if the patient is enrolled in a Medicaid Managed Care Organization (MMCO). Most NY MMCOs including Fidelis Care, HealthFirst, and MetroPlus follow similar clinical criteria. Approval turnaround is typically two to five business days for standard requests and 24 hours for urgent requests under New York's 2023 PA reform law, which set statutory response-time limits for managed care plans [3].

Once authorized, alendronate generic is placed on the preferred drug list and carries a nominal copay, often $1 or $3 per fill for Medicaid fee-for-service enrollees. Dual-eligible patients (Medicare and Medicaid) receive alendronate through Medicare Part D with state Medicaid paying the cost-sharing. For those patients, confirming that the Part D plan's formulary lists alendronate as a preferred generic before the plan year starts saves confusion at the pharmacy counter.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines state: "Bisphosphonates are recommended as first-line pharmacologic therapy for most patients with osteoporosis given their proven anti-fracture efficacy and favorable safety profile." [4] That guideline backing strengthens the clinical argument in a PA appeal if an initial request is denied.

Which Commercial Insurance Plans Cover Fosamax in New York?

Virtually every commercial plan sold through the New York State of Health marketplace covers generic alendronate. The drug appears on Tier 1 (preferred generic) of most formularies, meaning copays range from $0 to $10 per monthly fill. A minority of plans tier it at Tier 2 (non-preferred generic), raising the copay to roughly $10 to $40 per fill depending on the plan's cost-sharing structure.

Major NY carriers including Empire BlueCross BlueShield, MVP Health Care, EmblemHealth, Oscar Health, and UnitedHealthcare all listed generic alendronate as preferred generics on their 2026 NY individual and small-group formularies. Large self-insured employers in New York typically follow the same approach, given alendronate's inclusion on virtually every pharmacy benefit manager's (PBM) preferred drug list.

Medicare Part D deserves separate attention for patients aged 65 and older, who represent the largest population prescribed alendronate. In 2026, Medicare Part D plans must comply with the Inflation Reduction Act's $2,000 out-of-pocket cap, and alendronate's low list price means most Part D enrollees pay $0 to $5 per fill once they are in a plan with preferred-generic cost-sharing. Running the Medicare Plan Finder tool at medicare.gov before the October to December annual enrollment window remains the most reliable way to confirm coverage for the coming plan year.

Prior authorization is uncommon for alendronate under commercial plans because it is the least expensive first-line option for osteoporosis. If a plan does require PA, the clinical threshold mirrors Medicaid: a T-score at or below negative 2.5, or a fragility fracture history, generally satisfies the medical necessity requirement without further review.

Is Compounded Alendronate Legal in New York?

Compounding alendronate through a state-licensed 503A pharmacy is legal in New York. Strict oversight by the New York State Board of Pharmacy governs the practice, and not every compounding pharmacy in the state is equipped or willing to prepare alendronate formulations.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare drug products on a patient-specific, prescription basis when a commercially available product does not meet a patient's clinical need [5]. Common reasons a prescriber might order compounded alendronate in New York include: documented intolerance to the excipients in the commercial tablet, a requirement for a liquid suspension in patients with dysphagia, or enrollment in a patient assistance program offered through a 503A pharmacy that provides the compound at no cost.

Alendronate does NOT appear on the FDA's 503B outsourcing facility list of bulk-compounded drugs, which means large-scale 503B production of alendronate for office stock is not permitted. Prescriptions must go to a 503A pharmacy, and they must be written for a specific named patient. Any New York provider or patient exploring this route should confirm the pharmacy holds a current New York State Board of Pharmacy compounding registration before filling.

Some 503A pharmacies affiliated with telehealth platforms offer compounded alendronate at little or no charge to patients who cannot afford the commercial generic. The clinical product is equivalent in active ingredient but is not FDA-approved in the compounded form, a distinction patients should understand before switching from the commercially manufactured tablet.

Can You Get a Fosamax Prescription via Telehealth in New York?

Telehealth prescribing of alendronate is fully permitted in New York in 2026. New York State lifted its telehealth prescribing restrictions for non-controlled substances during the COVID-19 public health emergency and subsequently codified those permissions under the New York Telehealth Parity Law (Public Health Law Section 2999-cc), which requires commercial insurers to cover telehealth visits at parity with in-person visits [6].

A telehealth provider licensed in New York may review a patient's DXA scan results, fracture history, FRAX score, and relevant labs (renal function, serum calcium, vitamin D level), then issue a new prescription or refill for alendronate without an in-person visit. Controlled substance restrictions do not apply to alendronate, which simplifies the regulatory picture considerably.

For the telehealth visit to be billable and covered by insurance, the prescribing clinician must hold a current New York medical license (or be licensed in the state where the patient is physically located at the time of the visit, per interstate compact rules). Most large telehealth platforms operating in New York maintain NY-licensed physicians, nurse practitioners, or physician assistants for this purpose.

Bone density monitoring via DXA scan still requires an in-person facility visit, since the imaging equipment is not portable. The American College of Obstetricians and Gynecologists (ACOG) recommends DXA screening at age 65 for postmenopausal women and earlier for women with significant risk factors [7]. A telehealth provider can review prior DXA results and order a follow-up scan at a local imaging center, combining the convenience of remote prescribing with the clinical rigor of periodic in-person imaging.

Discount Programs and Savings Strategies for Alendronate in New York

Several concrete strategies reduce the out-of-pocket cost of alendronate in New York to near zero for eligible patients.

GoodRx and similar coupon aggregators. Free GoodRx coupons routinely bring generic alendronate 70 mg (4 tablets, 28-day supply) to $10 to $14 at major NY pharmacies. Presenting the coupon at the pharmacy counter substitutes for insurance billing; the patient pays the discounted cash price and the pharmacy processes it through GoodRx's contracted rates.

Merck Patient Assistance Program. Merck offers brand Fosamax at no charge to uninsured or underinsured patients who meet income thresholds through the Merck Patient Assistance Program (merck.com/patient-assistance-program). In New York, eligibility generally requires a household income at or below 400% of the federal poverty level and lack of coverage for the drug through any insurance plan. Applications require prescriber sign-off and take roughly two to four weeks to process.

New York State Pharmaceutical Assistance Contracts for the Elderly (PACE/PACENET). New York's PACE program provides drug benefits to income-eligible New Yorkers aged 65 and older. Alendronate is a covered drug under PACE. In 2026, PACE enrollees pay a $3 to $20 copay per prescription depending on income tier, which is competitive with or better than many Medicare Part D plans for this drug.

Extra Help / Low-Income Subsidy (LIS). Medicare enrollees who qualify for Extra Help pay no more than $4.50 for generic drugs in 2026 under the LIS program. A New York resident on Medicare who has not yet applied for Extra Help can do so through the Social Security Administration at ssa.gov or through a local NY HIICAP (Health Insurance Information, Counseling, and Assistance Program) counselor at no charge.

340B program pharmacies. Federally Qualified Health Centers (FQHCs) and certain qualifying hospitals in New York participate in the 340B Drug Pricing Program, which requires manufacturers to provide outpatient drugs at significantly reduced prices. Patients who receive care at a 340B-covered entity in New York may obtain alendronate at near-wholesale cost, often well below the retail generic price.

A 2021 Osteoporosis International analysis found that cost-related non-adherence to bisphosphonate therapy was associated with a 16% increase in osteoporotic fracture risk over five years, underscoring the clinical case for minimizing out-of-pocket costs [8].

Alendronate Dosing, Monitoring, and When to Expect Results in New York Clinical Practice

The standard FDA-approved dose for postmenopausal osteoporosis in New York clinical practice matches the national standard: 70 mg taken orally once weekly. An alternative 10 mg daily regimen exists on the label but is prescribed rarely because the weekly formulation produces equivalent anti-fracture efficacy with simpler adherence [1].

Correct administration technique matters as much as the dose itself. Patients must take the tablet first thing in the morning with at least 240 mL (8 oz) of plain water, remain upright (sitting or standing) for at least 30 minutes after ingestion, and eat nothing during that interval. Lying down after taking alendronate significantly raises the risk of esophageal irritation and pill esophagitis, the most common reason patients discontinue the drug [9].

Before starting alendronate, baseline labs should confirm adequate renal function (estimated GFR at or above 35 mL/min/1.73 m²) and rule out hypocalcemia. Patients with severe renal impairment (eGFR <35) should not receive alendronate. Pre-treatment vitamin D supplementation (at least 800 IU daily) reduces the risk of hypocalcemia during therapy and is standard of care per the National Osteoporosis Foundation.

DXA monitoring after starting therapy is typically repeated at 24 months for postmenopausal women treated in accordance with AACE guidelines. Bone mineral density increases are modest (typically 2% to 8% at the lumbar spine over two years) but fracture risk reduction exceeds what the BMD change alone would predict, because bisphosphonates also improve bone quality at the microarchitectural level.

Treatment duration requires individualized discussion. After five years of oral bisphosphonate therapy, a "drug holiday" of one to three years may be appropriate for lower-risk patients, while higher-risk patients (prior hip fracture, very low T-score, ongoing glucocorticoid therapy) generally continue therapy beyond five years. A 2022 JAMA Internal Medicine systematic review found no significant increase in atypical femur fracture risk at durations below five years, with risk rising modestly after six or more years of continuous use [10].

Osteonecrosis of the Jaw and Atypical Femur Fractures: How Significant Is the Risk in Practice?

Both osteonecrosis of the jaw (ONJ) and atypical femur fractures (AFF) are genuine but rare adverse effects that disproportionately affect patients on very long-term or very high-dose bisphosphonate therapy. The absolute risk numbers matter here.

ONJ incidence in patients taking oral alendronate for osteoporosis runs approximately 1 in 10,000 to 1 in 100,000 patient-treatment years, compared with 1 in 10 to 1 in 100 in oncology patients receiving intravenous bisphosphonates at oncologic doses [11]. For an osteoporosis patient in New York taking weekly oral alendronate, the ONJ risk is clinically negligible when weighed against the 10-year fracture probability that justified starting therapy.

AFF risk is similarly context-dependent. A large Swedish cohort study (N=12,777 patients with AFF) found that bisphosphonate use doubled the relative risk of AFF, but the absolute risk over a five-year course was approximately 11 per 100,000 women, compared with 2,000 hip fractures per 100,000 women prevented over the same period [12]. The ratio strongly favors continued therapy in patients with established osteoporosis.

Patients should report any new thigh or groin pain that develops after several years of alendronate use. That symptom may represent a prodromal stress reaction preceding AFF and warrants plain radiograph evaluation before the fracture completes.

New York-Specific Prescriber and Patient Resources for Alendronate

New York offers several state-specific resources that complement federal programs.

The New York State Department of Health maintains an online formulary tool at health.ny.gov that lets prescribers verify current Medicaid prior-authorization requirements for alendronate in real time. The tool is updated quarterly and reflects the most current preferred drug list status.

NY HIICAP counselors provide free, unbiased Medicare counseling at over 500 sites across the state and can help patients compare Part D plans by their out-of-pocket cost for alendronate specifically. The HIICAP helpline is (800) 701-0501.

The Hospital for Special Surgery (HSS) Osteoporosis Prevention Center in Manhattan operates a bone health clinic that accepts most NY insurance plans including Medicaid and Medicare. HSS also runs a patient education program on bisphosphonate adherence that has been cited in peer-reviewed literature as a model for improving long-term medication persistence [13].

The Endocrine Society's 2019 Pharmacological Management of Osteoporosis guideline advises: "In postmenopausal women with osteoporosis, we recommend pharmacological treatment to reduce the risk of fractures. Bisphosphonates are recommended as initial therapy in most patients." [14] That recommendation, from a named guideline body, carries weight when navigating insurance coverage disputes in New York.

For uninsured New Yorkers who still face barriers after exhausting discount programs, the New York State Office for the Aging's Aged, Blind, and Disabled Medicaid pathway may confer eligibility for patients who did not previously qualify under standard income thresholds. An elder law attorney or a social worker at any major NY hospital can initiate this pathway.